Mandate

Vinge advises Odevo in connection with the acquisition of OBOS’ 40% minority stake in SBC and OBOS subsequent investment in Odevo

April 13, 2022 M&A

Vinge advises Odevo in connection with the acquisition of OBOS minority stake of approx. 40 percent in SBC Intressenter HoldCo AB ("SBC") and OBOS’ subsequent investment in Odevo.

OBOS has been a minority investor in SBC since 2019. Through the divestment of its shares in SBC to Odevo, SBC becomes wholly owned by Odevo. Odevo was launched in February and is a new international player that challenges the traditional industry for property and housing management. The foundation for the group was created in 2019 through the formation of Nabo and the acquisition of SBC, and since then the group has grown into a leading international player. The companies within Odevo offer services to residents and property owners supported by Odevo’s own developed platform. The Odevo Group consists of a total of approximately 1,300 employees and has a turnover of just over SEK 1.5 billion.

Vinge’s team consisted of among others Jonas Bergstöm, Joacim Rydergård and Clara Sohlberg.

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025